natgillin/translations-raw huggingface dataset:
Progressionsfri overlevelse (PFS) og størrelsen af det totale respons var ens mellem de to behandlingsarme: Middel PFS var 4,8 måneder for pemetrexed plus cisplatin mod 5,1 måneder for gemcitabin plus cisplatin (justeret hazard ratio 1.04; 95 % CI = 0,94-1,15) og det totale respons var 30,6 % (95 % CI = 27,3- 33,9) for pemetrexed plus cisplatin mod 28,2 % (95 % CI = 25,0-31,4) for gemcitabin plus cisplatin.
Progression-free survival (PFS) and overall response rate were similar between treatment arms: median PFS was 4.8 months for pemetrexed plus cisplatin versus 5.1 months for gemcitabine plus cisplatin (adjusted hazard ratio (HR) 1.04; 95% CI= 0.94-1.15), and overall response rate was 30.6% (95% CI= 27.3- 33.9) for pemetrexed plus cisplatin versus 28.2% (95% CI= 25.0-31.4) for gemcitabine plus cisplatin.
Progressionsfri overlevelse (PFS)* D primær analyse
Progression free survival (PFS)* - primary analysis
Progressionsfri overlevelse (PFS)*** D opfølgende analyse
Progression free survival (PFS)*** - follow-up analysis
Progressionsfri overlevelse (PFS), N
Progression free survival (PFS), N
Progressionsfri overlevelse (PFS), vurderet af IRC i henhold til kriterierne fra IWCLL (International Workshop on CLL), indikerede en statistisk signifikant reduktion på 84 % af risikoen for død eller progression i IMBRUVICA-gruppen.
Progression free survival (PFS) as assessed by IRC according to International Workshop on CLL (IWCLL) criteria indicated an 84% statistically significant reduction in the risk of death or progression in the IMBRUVICA arm.
Progressionsfri overlevelse (PFS)a
Progression-Free Survival (PFS)a
Progressionsfri overlevelse (PFS)a efter en post-hoc, retrospektiv uafhængig gennemgang
Progression-free survival (PFS)a by Post-hoc Retrospective Independent Review
Progressionsfri overlevelse (PFS)a efter investigators bedømmelse
Progression-free survival (PFS)a by Investigator Assessment
Progressionsfri overlevelse (PFS)b
Progression Free Survival
Progressionsfri overlevelse (primær analyse)6
Progression-free survival – Primary analysis6
Progressionsfri overlevelse (uafhængigt vurderet) - Primært endepunkt*
Progression-Free Survival (independent review) – primary endpoint
Progressionsfri overlevelse - total Median (måneder)e (95% konfidensinterval)d
PFS - overall Median (months)e (95% CI)d
Progressionsfri overlevelse [median, måneder (95% CI)] ved blindet, uafhængig, central gennemgang af tumor-vurdering
Progression-Free Survival [median, months (95% CI)] by blinded independent central review of tumour assessments
Progressionsfri overlevelse [median, måneder (95% CI)] ved investigator- vurdering
Progression-Free Survival [median, months (95% CI)] by Investigator Assessment
Progressionsfri overlevelse [median, måneder (95% CI)] ved respons- vurdering baseret på RECIST sammenholdt med investigator- tumor-måling
Progression-Free Survival [median, months (95% CI)] by derived tumour response assessment based upon application of RECIST to investigator tumour assessments
Progressionsfri overlevelse blev defineret som objektiv evidens for radiografisk sygdomsprogression ved uafhængig central vurdering, skeletrelaterede hændelser, initiering af ny antineoplastisk behandling eller død uanset årsag afhængigt af, hvad der indtraf først.
Progression-free survival was defined as objective evidence of radiographic disease progression by independent central review, skeletal-related events, initiation of new antineoplastic therapy or death by any cause, whichever occurred first.
Progressionsfri overlevelse blev evalueret i flere relevante undergrupper: køn, race, ECOG- præstationsstatus, stratifikationsfaktorer (alder, sygdomspopulation, tidligere antimyelom- behandlinger [2, > 2], udvalgte parametre af prognostisk signifikans (beta-2-mikroglobulinniveau, albuminniveau og nedsat nyrefunktion ved baseline samt cytogenetisk risiko) samt eksponering og refraktær tendens ved tidligere anti-myelom-behandlinger.
Progression-free survival was evaluated in several relevant subgroups: gender, race, ECOG performance status, stratification factors (age, disease population, prior anti-myeloma therapies [2, > 2]), selected parameters of prognostic significance (baseline beta-2 microglobulin level, baseline albumin levels, baseline renal impairment, and cytogenetic risk), and exposure and refractoriness to prior anti-myeloma therapies.
Progressionsfri overlevelse efter 6 måneder
Progression-free Survival after 6 months
Progressionsfri overlevelse er opsummeret i Tabel 1 for ITT-populationen.
Progression Free Survival is summarised in Table 1 for the ITT population.
Progressionsfri overlevelse i henhold til investigator (måneder) Antal forsøgspersoner i risikogruppe
Progression Free Survival per Investigator (Months) Number of Subjects at Risk
Progressionsfri overlevelse i PIX301 ved studiets slutning
PIX301 Progression-free survival - end of study
Progressionsfri overlevelse Median måneder
Progression-Free Survival, Median months
Progressionsfri overlevelse Median, måneder (95 % KI)
Median, Months (95% CI)
Progressionsfri overlevelse Median, måneder (95 % KI)
Progression-free survival
Progressionsfri overlevelse Måneder (median)
Progression-free survival Months (median)
Progressionsfri overlevelse og hændelsesfri overlevelse udgjorde de tertiære endepunkter.
Progression-free survival and Event- free survival were tertiary endpoints.
Progressionsfri overlevelse og objektiv responsrate var inferior i Avastin monoterapi-armen i forhold til FOLFOX-4- armen.
Progression-free survival and objective response rate were inferior in the Avastin monotherapy arm compared to the FOLFOX-4 arm.
Progressionsfri overlevelse og størrelsen af det totale respons var ens for de to behandlingsarme: Median progressionsfri overlevelse var 4,8 måneder for pemetrexed plus cisplatin versus 5,1 måneder for gemcitabin plus cisplatin (justeret hazard ratio 1.04; 95 % CI = 0,94-1,15) og det totale respons var 30,6 % (95 % CI = 27,3- 33,9) for pemetrexed plus cisplatin versus 28,2 % (95 % CI = 25,0-31,4) for gemcitabin plus cisplatin.
Progression free survival (PFS) and overall response rate were similar between treatment arms: median PFS was 4.8 months for pemetrexed plus cisplatin versus 5.1 months for gemcitabine plus cisplatin (adjusted hazard ratio 1.04; 95% CI = 0.94-1.15), and overall response rate was 30.6% (95% CI = 27.3-33.9) for pemetrexed plus cisplatin versus 28.2% (95% CI = 25.0-31.4) for gemcitabine plus cisplatin.
Progressionsfri overlevelse og størrelsen af det totale respons var ens for de to behandlingsarme: Median progressionsfri overlevelse var 4,8 måneder for pemetrexed plus cisplatin versus 5,1 måneder for gemcitabin plus cisplatin (justeret hazard ratio 1.04; 95 % CI = 0,94-1,15) og det totale respons var 30,6 % (95 % CI = 27,3–33,9) for pemetrexed plus cisplatin versus 28,2 % (95 % CI = 25,0–31,4) for gemcitabin plus cisplatin.
Progression free survival (PFS) and overall response rate were similar between treatment arms: median PFS was 4.8 months for pemetrexed plus cisplatin versus 5.1 months for gemcitabine plus cisplatin (adjusted hazard ratio 1.04; 95% CI = 0.94-1.15), and overall response rate was 30.6% (95% CI = 27.3-33.9) for pemetrexed plus cisplatin versus 28.2% (95% CI = 25.0-31.4) for gemcitabine plus cisplatin.
Progressionsfri overlevelse Samlet overlevelse
Progression-Free Survival Overall Survival
Progressionsfri overlevelse Total overlevelse
Progression-Free Survival Overall Survival
Progressionsfri overlevelse Total overlevelse (OS)
Progression-Free Survival Overall Survival
Progressionsfri overlevelse var statistisk signifikant forbedret hos de patienter, der fik Cyramza plus FOLFIRI, sammenlignet med dem, der fik placebo plus FOLFIRI (HR 0,793; 95 % KI: 0,697-0,903; p=0,0005).
Progression-free survival was statistically significantly improved in patients receiving Cyramza plus FOLFIRI compared with those receiving placebo plus FOLFIRI (HR 0.793; 95% CI: 0.697 to 0.903; p=0.0005).
Progressionsfri overlevelse vurderet af en uafhængig bedømmelseskomité
IRC-assessed progression-free survival (PFS)
Progressionsfri overlevelse vurderet af en uafhængig komité
IRC-assessed PFS (PFS-IRC)
Progressionsfri overlevelse*
Progression-Free Survival
Progressionsfri overlevelse**
Progression Free Survival
Progressionsfri overlevelse,
Progression free survival
Progressionsfri overlevelse, måneder
Progression Free Survival, months
Progressionsfri overlevelse, måneder*
Progression free survival, months
Progressionsfri overlevelse1,2
Progression-Free Survival1,2
Progressionsfri overlevelsea
Progression free survivala
Progressionsfri overlevelsea
Progression-Free Survivala
Progressionsfri overlevelseb [median (95% CI)] måneder
Progression-Free Survivalb [median (95% CI)] months
Progressionsfri overlevelsec [median (95% CI)] måneder
Progression-Free Survivalc [median (95% CI)] months
Progressionsfri overlevelsestid (uger)
Progression Free Survival Time(weeks)
Progressionshastigheden af strukturel skade var signifikant mindre det andet år sammenlignet med det første år hos patienter, som var randomiseret til abatacept (p < 0,0001).
The rate of progression of structural damage in year 2 was significantly lower than that in year 1 for patients randomized to abatacept (p < 0.0001).
Progressionstid (TTP) var det primære endepunkt.
Time to progression (TTP) was the primary endpoint.
Progressiv multifokal leukoencefalopati (PML) er blevet rapporteret ved Jakavi-behandling for MF.
Progressive multifocal leukoencephalopathy (PML) has been reported with Jakavi treatment for MF.
Progressiv multifokal leukoencefalopati (PML) er en alvorlig og livstruende infektion i hjernen.
Progressive multifocal leukoencephalopathy (PML) is a serious and life threatening brain infection.
Progressiv multifokal leukoencefalopati (PML) er rapporteret hos patienter med B-CLL med eller uden behandling med alemtuzumab.
Progressive multifocal leukoencephalopathy (PML) has been reported in patients with B-CLL with or without treatment with alemtuzumab.
Progressiv multifokal leukoencefalopati (PML) Kryptokokinfektioner
Progressive multifocal leukoencephalopathy (PML) Cryptococcal infections
Progressiv multifokal leukoencefalopati (PML), der er en alvorlig og livstruende tilstand i hjernen, er rapporteret ved brug af medicin som Arzerra.
Progressive multifocal leukoencephalopathy (PML), a serious and life threatening brain condition, has been reported with medicines like Arzerra.
Progressiv multifokal leukoencefalopati er en meget sjælden, men livstruende hjernebetændelse, der er set hos meget få patienter, der har fået Gazyvaro.
PML is a very rare and life-threatening brain infection that has been reported in very few patients having treatment with Gazyvaro.
Progressiv sygdom
Progressive disease
Progressiv sygdom (PD)
18 (10.6)
Progressiv sygdom (PD)
Progressive disease (PD)
Progressiv sygdom som bedste overlevelse respons (%)
Progressive Disease as Best Overall Response (%)
Progressiv sygdom som bedste overordnede respons (%)
Progressive disease as best overall response (%)
Progressiv sygdom som bedste respons
Progressive Disease as Best Response
Progressiv sygdom som bedste totale respons (%)
Progressive Disease as Best Overall Response (%)
Progressiv sygdom Ukendt
Progressive Disease Unknown
Progressiv sygdom‡
Progressive disease
Progressive neuroendokrine tumorer udgået fra mave-tarm-kanalen eller lungerne
Advanced neuroendocrine tumours of gastrointestinal or lung origin
Progressive neuroendokrine tumorer udgået fra pancreas (pNET)
Advanced neuroendocrine tumours of pancreatic origin (pNET)
progressive, eller
progressive, or
progressivt, eller
progressive, or
Projiceret ivacaftor-eksponering, baseret på observerede ivacaftor-koncentrationer i fase 2- og 3- studier bestemt ved hjælp af den populationsfarmakokinetiske analyse er vist pr. aldersgruppe i tabel 6.
Predicted ivacaftor exposure based on observed ivacaftor concentrations in Phase 2 and 3 studies as determined using population PK analysis is presented by age group in Table 6.
Proksimal renal tubulopati gik generelt væk eller blev bedre efter seponering af tenofovirdisoproxilfumarat.
Proximal renal tubulopathy generally resolved or improved after tenofovir disoproxil fumarate discontinuation.
proksimal renal tubulopati, herunder Fanconis syndrom3, øget kreatinin3, proteinuri3
proximal renal tubulopathy including Fanconi syndrome3, increased creatinine3, proteinuria3
proktitd
proctitisd
Proktitis, pancreatitis
proctitis, pancreatitis
Prolaktinhæmmer
NO ENTRY
Prolia 60 mg injektion denosumab
Prolia 60 mg injection denosumab
Prolia 60 mg injektionsvæske, opløsning, i fyldt injektionssprøjte
Prolia 60 mg solution for injection in a pre-filled syringe
Prolia 60 mg injektionsvæske, opløsning, i fyldt injektionssprøjte denosumab
Prolia 60 mg solution for injection in a pre-filled syringe denosumab
Prolia anbefales ikke til gravide.
Prolia is not recommended for use in pregnant women.
Prolia anvendes også til at behandle tab af knoglemasse hos mænd, der er i behandling for prostatakræft, da denne behandling øger risikoen for brud.
Prolia is also used to treat bone loss in men receiving treatment for prostate cancer that increases their risk of fracture.
Prolia anvendes til behandling af osteoporose (en sygdom, som gør knoglerne skrøbelige) hos kvinder, som har været gennem overgangsalderen, og hos mænd, som har forhøjet risiko for knoglebrud.
Prolia is used to treat osteoporosis (a disease that makes bones fragile) in women who have been through the menopause and in men who have an increased risk of fracture (broken bones).
Prolia bør ikke anvendes til patienter med sjælden arvelig fructoseintolerans.
Patients with rare hereditary problems of fructose intolerance should not use Prolia.
Prolia er en injektionsvæske, opløsning, der indeholder det aktive stof denosumab.
Prolia is a solution for injection that contains the active substance denosumab.
Prolia er en klar, farveløs til let gul injektionsvæske, opløsning, som leveres i en fyldt injektionssprøjte, der er klar til brug.
Prolia is a clear, colourless to slightly yellow solution for injection provided in a ready to use pre- filled syringe.
Prolia gives hver sjette måned ved en 60 mg-injektion under huden i låret, abdomen (maven) eller på bagsiden af armen.
Prolia is given once every six months as a 60 mg injection under the skin in the thigh, abdomen (tummy) or back of the arm.
Prolia gives som en injektion i vævet lige under huden (subkutan injektion).
Prolia is given as an injection into the tissue just under the skin (subcutaneous injection).
Prolia indeholder sorbitol (E420)
Prolia contains sorbitol (E420)
Prolia kan opbevares ved stuetemperatur (op til 25 °C) i op til 30 dage i den originale beholder.
Prolia may be stored at room temperature (up to 25°C) for up to 30 days in the original container.
Prolia mindsker risikoen for brud i rygsøjlen.
Prolia reduces the risk of fractures in the spine.
Prolia må ikke gives til patienter med hypocalcæmi (lavt calciumindhold i blodet).
Prolia must not be used in people with hypocalcaemia (low blood calcium levels).
Prolia n = 3.902
Prolia n = 3,902
Prolia nedsatte frakturer signifikant på tværs af alle frakturtyper/-grupper (se tabel 3).
Prolia significantly reduced fractures across all fracture types/groups (see table 3).
Prolia skal anvendes inden for dette tidsrum på 30 dage, efter at det er taget ud af køleskabet.
Once removed from the refrigerator, Prolia must be used within this 30 day period.
Prolia var også mere effektivt til at mindske antallet af kvinder, der fik brud andre steder i kroppen, herunder hoften.
Prolia was also more effective at reducing the number of women who had fractures elsewhere in the body, including in the hip.
Prolias generelle sikkerhedsprofil i fem fase III placebo-kontrollerede kliniske studier var ens for patienter med osteoporose og patienter med bryst- eller prostatacancer, der fik antihormonbehandling.
The overall safety profile of Prolia was similar in patients with osteoporosis and in breast or prostate cancer patients receiving hormone ablation in five Phase III placebo-controlled clinical trials.
Proliferationen af aktiverede B- og T-lymfocytter og udviklingen af cytotoksiske T-celler og immunoglobulinudskillende celler øges.
Proliferation of activated B- and T-lymphocytes, development of cytotoxic
Proliferativ retinopati, diabetisk retinopati, synsforstyrrelser
Proliferative retinopathy; Diabetic retinopathy; Visual impairment
Prolin, iseddike, polysorbat 80, natriumhydroxid, vand til injektion
Proline, glacial acetic acid, polysorbate 80, sodium hydroxide, water for injections.
Prolin, iseddike, polysorbat 80, natriumhydroxid, vand til injektion.
Proline, glacial acetic acid, polysorbate 80, sodium hydroxide, water for injections.
ProMeris 160 mg Spot-on, opløsning til små katte ProMeris 320 mg Spot-on, opløsning til store katte
ProMeris 160 mg Spot-on for small cats ProMeris 320 mg Spot-on for large cats
ProMeris 160 mg Spot-on, opløsning til små katte ProMeris 320 mg Spot-on, opløsning til store katte
ProMeris 160 mg Spot-on solution for small cats ProMeris 320 mg Spot-on solution for large cats
ProMeris 160 mg Spot-on, opløsning til små katte {≤ 4 kg}
ProMeris 160 mg Spot-on for small cats {< 4 kg}
ProMeris 320 mg Spot-on, opløsning til store katte {> 4 kg}
ProMeris 320 mg Spot-on for large cats {> 4 kg}
ProMeris Duo 100,5 mg + 100,5 mg Spot-on, opløsning til små hunde {≤ 5 kg}
ProMeris Duo 100.5 mg + 100.5 mg Spot-on for small dogs {≤ to 5 kg}
ProMeris Duo 100,5 mg + 100,5 mg, Spot-on, opløsning til små hunde ProMeris Duo 199,5 mg + 199,5 mg, Spot-on, opløsning til mellemstore hunde
ProMeris Duo 100.5 mg + 100.5 mg Spot-on for small dogs ProMeris Duo 199.5 mg + 199.5 mg Spot-on for medium sized dogs
ProMeris Duo 199,5 mg + 199,5 mg Spot-on, opløsning til mellemstore hunde {5,1 – 10,0 kg}
ProMeris Duo 199.5 mg + 199.5 mg Spot-on for medium sized dogs {5.1 – 10.0 kg}
ProMeris Duo 499,5 mg + 499,5 mg Spot-on, opløsning til mellemstore-store hunde {10,1 – 25,0 kg}
ProMeris Duo 499.5 mg + 499.5 mg Spot-on for medium/large sized dogs {10.1 – 25.0 kg}
ProMeris Duo 499,5 mg + 499,5 mg, Spot-on, opløsning til mellemstore-store hunde ProMeris Duo 799,5 mg + 799,5 mg, Spot-on, opløsning til store hunde
ProMeris Duo 499.5 mg + 499.5 mg Spot-on for medium/large sized dogs ProMeris Duo 799.5 mg + 799.5 mg Spot-on for large dogs
ProMeris Duo 499,5 mg + 499,5 mg, Spot-on, opløsning til mellemstore-store hunde ProMeris Duo 799,5 mg + 799,5 mg, Spot-on, opløsning til store hunde ProMeris Duo 999 mg + 999 mg, Spot-on, opløsning til ekstra store hunde
ProMeris Duo 499.5 mg + 499.5 mg Spot-on for medium/large sized dogs ProMeris Duo 799.5 mg + 799.5 mg Spot-on for large dogs ProMeris Duo 999 mg + 999mg Spot-on for extra large dogs
ProMeris Duo 799,5 mg + 799,5 mg Spot-on, opløsning til store hunde {25,1 – 40,0 kg}
ProMeris Duo 799.5 mg + 799.5 mg Spot-on for large dogs {25.1 – 40.0 kg}
ProMeris Duo 999 mg + 999 mg Spot-on, opløsning til ekstra store hunde {40,1 – 50,0 kg}
ProMeris Duo 999 mg + 999 mg Spot-on for extra large dogs {40.1 – 50.0 kg}
ProMeris Duo 999 mg + 999 mg, Spot-on, opløsning til ekstra store hunde
ProMeris Duo 999 mg + 999mg Spot-on for extra large dogs
ProMeris Duo anvendes til hunde, som er over otte uger gamle, til behandling og forebyggelse af flåt- og loppeangreb og til behandling af demodicosis (forårsaget af Demodex-mider) og
ProMeris Duo is used in dogs over eight weeks of age to treat and to prevent tick and flea infestations, and to treat demodicosis (caused by Demodex mites) and lice infestations.
ProMeris Duo er et “ektoparasiticid”.
ProMeris Duo is an ‘ectoparasiticide’.
ProMeris Duo indeholder stoffer, som i meget sjældne tilfælde kan forårsage åndedrætsbesvær hos enkelte personer .
ProMeris Duo contains components that, on very rare occasions, can cause respiratory irritation in certain people.
ProMeris Duo L Spot-on, opløsning
ProMeris Duo L Spot-on solution
ProMeris Duo M Spot-on, opløsning
ProMeris Duo M Spot-on solution
ProMeris Duo M/L Spot-on, opløsning
ProMeris Duo M/L Spot-on solution
ProMeris Duo S Spot-on, opløsning
ProMeris Duo S Spot-on solution
ProMeris Duo til ekstra store hunde
ProMeris Duo for Extra Large Dogs
ProMeris Duo til ekstra store hunde
ProMeris Duo Spot-on for Extra Large Dogs
ProMeris Duo til mellemstore hunde
ProMeris Duo Medium Sized Dogs
ProMeris Duo til mellemstore-store hunde
ProMeris Duo for Medium/Large Sized Dogs
ProMeris Duo til mellemstore-store hunde
ProMeris Duo Spot-on for Medium/Large Sized Dogs
ProMeris Duo til små hunde
ProMeris Duo for Small Dogs
ProMeris Duo til store hunde
ProMeris Duo for Large Dogs
ProMeris Duo til store hunde
ProMeris Duo Spot-on for Large Dogs
ProMeris Duo XL Spot-on, opløsning
ProMeris Duo XL Spot-on solution
ProMeris Spot-on, opløsning til katte
ProMeris Spot-on for cats
ProMeris til små katte
ProMeris for Small Cats
ProMeris til små katte (≤ 4 kg)
ProMeris for Small Cats (≤ 4 kg)
ProMeris til små katte (≤ 4 kg)*
ProMeris for Small Cats (≤ 4 kg)
ProMeris til store katte
ProMeris for Large Cats
ProMeris til store katte (>4 kg)*
ProMeris for Large Cats (> 4 kg)
Prometax 1,5 mg hårde kapsler, som indeholder et råhvidt til svagt gulligt pulver, har en gul hætte og en gul skal, med ” ENA 713 1,5 mg”, der er præget med rødt på kapselskallen.
Prometax 1.5 mg hard capsules, which contain an off-white to slightly yellow powder, have a yellow cap and yellow body, with red imprint “ENA 713 1,5 mg” on the body.
Prometax 13,3 mg/24 timer
Prometax 13.3 mg/24 h
Prometax 2 mg/ml
Prometax 2 mg/ml [folding box only]
Prometax 3,0 mg hårde kapsler, som indeholder et råhvidt til svagt gulligt pulver, har en orange hætte og en orange skal, med ” ENA 713 3 mg”, der er præget med rødt på kapselskallen.
Prometax 3.0 mg hard capsules, which contain an off-white to slightly yellow powder, have an orange cap and orange body, with a red imprint “ENA 713 3 mg” on the body.
Prometax 4,5 mg hårde kapsler, som indeholder et råhvidt til svagt gulligt pulver, har en rød hætte og en rød skal, med ” ENA 713 4,5 mg”, der er præget med hvidt på kapselskallen.
Prometax 4.5 mg hard capsules, which contain an off-white to slightly yellow powder, have a red cap and red body, with a white imprint “ENA 713 4,5 mg” on the body.
Prometax 4,6 mg/24 timer
Prometax 4.6 mg/24 h
Prometax 6,0 mg hårde kapsler, som indeholder et råhvidt til svagt gulligt pulver, har en rød hætte og en orange skal, med ” ENA 713 6 mg”, der er præget med rødt på kapselskallen.
Prometax 6.0 mg hard capsules, which contain an off-white to slightly yellow powder, have a red cap and orange body, with a red imprint “ENA 713 6 mg” on the body.
Prometax 9,5 mg/24 timer
Prometax 9.5 mg/24 h
Prometax anvendes til behandling af patienter med let til middelsvær Alzheimers sygdom, en fremadskridende hjernesygdom, der gradvis angriber hukommelse, intellektuelle evner og adfærd.
Prometax is used for the treatment of patients with mild to moderately severe Alzheimer’s dementia, a progressive brain disorder that gradually affects memory, intellectual ability and behaviour.
Prometax anvendes til behandling af voksne patienter med mild til moderat svær Alzheimers demens, en fremadskridende hjernesygdom, der gradvis påvirker hukommelse, åndsevner og adfærd.
Prometax is used for the treatment of adult patients with mild to moderately severe Alzheimer’s dementia, a progressive brain disorder that gradually affects memory, intellectual ability and behaviour.
Prometax blev undersøgt ved let til middelsvær Alzheimers sygdom.
Prometax has been studied in mild to moderately severe Alzheimer’s disease.
Prometax depotplastre er tynde, uigennemsigtigte plast-plastre, som klæber til huden.
Prometax patches are thin, opaque, plastic patches that stick to the skin.
Prometax indeholder:
What Prometax contains
Prometax kan påvirke antikolinerg medicin (medicin, der bruges mod mavekramper og Parkinsons sygdom eller til at forebygge transportsyge).
Prometax might interfere with anticholinergic medicines (medicines used to relieve stomach cramps or spasms, to treat Parkinson’s disease or to prevent travel sickness).